BioSpace News Archive

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced an expanded research collaboration with Cancer Research UK and the University of Manchester, UK, to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).

HORAMA, a clinical stage gene therapy company in ophthalmology, announced that Rodolphe Clerval has been appointed as Chief Business Officer.

The Exclusive Research Report on “Acute Lymphocytic/Lymphoblastic Leukemia Treatment Market with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029”.

Intabio, Inc. and Protein Metrics Inc., developers of advanced analytical tools for accelerating biopharmaceutical development and manufacturing, today announced a co-development and co-marketing agreement to couple Intabio’s Blaze™ instrument system with the Byos® software suite from Protein Metrics

Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders will release its financial results for the fourth quarter and full year ended December 31, 2019,

Conatus Pharmaceuticals Inc. announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process.

MedChi CTO Partners with DrFirst to Provide Backline with Telehealth for its Physician Practices

ADVANZ PHARMA Corp. Limited announced it intends to release its fourth quarter and 2019 financial results before market open on Wednesday, March 25, 2020.

Health Canada is informing Canadians, healthcare professionals, and manufacturers about a series of cybersecurity vulnerabilities named “SweynTooth”.

Globus Medical, Inc., a leading musculoskeletal solutions company, announced the Board of Directors authorized the repurchase of $200 million of the Company’s common stock.